• Foundation Fighting Blindness Retinal Degeneration Fund sold 1.7 million Opus Genetics common shares at USD 4.35 on May 18, 2026.
• Its stake fell to 3,792,171 shares following the sale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002042266-26-000001), on May 20, 2026, and is solely responsible for the information contained therein.